Five things for pharma marketers to know: Thursday, July 28, 2016

1. Vertex Pharmaceuticals told investors that its cystic-fibrosis drug Orkambi is on track to generate $1 billion in sales in 2016. It also said it expects Kalydeco, its other cystic-fibrosis drug, will generate between $685 million and $705 million in sales this year. (The Boston Globe)

2. Advent International and CVC Capital Partners made offers to acquire inVentiv Health, sources told Reuters. InVentiv, which had filed for an IPO earlier this year, is currently owned by Thomas H. Lee Partners, a private-equity firm. (Reuters)

3. The FDA approved Adlyxin (lixisenatide), Sanofi's once-daily mealtime GLP-1 receptor agonist injection for people with type 2 diabetes.  

4. Teva Pharmaceutical Industries will be allowed to acquire Allergan's generics business after agreeing to divest 79 generic drugs. This represents the largest pharmaceutical divestiture mandated by the Federal Trade Commission. (Modern Healthcare)

5. ICYMI: The $115 million raised by the Ice Bucket Challenge, a fundraiser for the ALS Association and a social-media phenomenon, was used to fund research that led to the discovery of the NEK1 gene, which is associated with 3% of ALS cases. (NYT)